Skip to content

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

By

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”